Cytokine induced apoptosis in human retinoblastoma cells

Molecular Vision

Volumn 10, Issue , 2004, Pages 315-322

  Cullinan, Amy E ^a,b   Brandt, Curtis R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CASPASE 3; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASPASE; INTERFERON RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENT ANTIBODY TECHNIQUE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETINOBLASTOMA; CELL CULTURE; DNA REPLICATION; DRUG COMBINATION; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; RETINA TUMOR;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; DNA REPLICATION; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; RECEPTORS, INTERFERON; RECEPTORS, TUMOR NECROSIS FACTOR; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342655801     PISSN: 10900535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999; 36:8-18.
2. Shields CL, Shields JA, De Potter P. New treatment modalities for retinoblastoma. Curr Opin Ophthalmol 1996; 7:20-6.
3. Chan HS, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991; 98:1425-31.
4. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1339-43.
5. Murphree AL, Villablanca JG, Deegan WF 3rd, Sato JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1348-56.
6. Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, Ling V, Chan HS. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114:1321-8. Erratum in: Arch Ophthalmol 1997; 115:525.
7. Schueler AO, Jurklies C, Heimann H, Wieland R, Havers W, Bornfeld N. Thermochemotherapy in hereditary retinoblastoma. Br J Ophthalmol 2003; 87:90-5.
8. Grostern RJ, Bryar PJ, Zimbric ML, Darjatmoko SR, Lissauer BJ, Lindstrom MJ, Lokken JM, Strugnell SA, Albert DM. Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. Arch Ophthalmol 2002; 120:607-12.
9. Sabet SJ, Darjatmoko SR, Lindstrom MJ, Albert DM. Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors. Arch Ophthalmol 1999; 117:365-70.
10. Shternfeld IS, Lasudry JG, Chappell RJ, Darjatmoko SR, Albert DM. Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. Arch Ophthalmol 1996; 114:1396-401.
11. Wilkerson CL, Darjatmoko SR, Lindstrom MJ, Albert DM. Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice. Clin Cancer Res 1998; 4:2253-6.
12. Brandt CR, Imesch PD, Robinson NL, Syed NA, Untawale S, Darjatmoko SR, Chappell RJ, Heinzelman P, Albert DM. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology 1997; 229:283-91.
13. Kogishi J, Miyatake S, Hangai M, Akimoto M, Okazaki K, Honda Y. Mutant herpes simplex virus-mediated suppression of retinoblastoma. Curr Eye Res 1999; 18:321-6.
14. Nicolo M, Chiocca EA. Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Res 1998; 30:30-6.
15. Hurwitz MY, Marcus KT, Chevez-Barrios P, Louie K, Aguilar-Cordova E, Hurwitz RL. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther 1999; 10:441-8.
16. Conway RM, Madigan MC, Penfold PL, Billson FA. Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line. Oncol Res 1995; 7:289-97.
17. Di Felice V, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol 1998; 13:225-32.
18. Vento R, Giuliano M, Lauricella M, Carabillo M, Di Liberto D, Tesoriere G. Induction of programmed cell death in human retinoblastoma Y79 cells by C2-ceramide. Mol Cell Biochem 1998; 185:7-15.
19. Giuliano M, Lauricella M, Calvaruso G, Carabillo M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 1999; 59:5586-95.
20. Giuliano M, Lauricella M, Vassallo E, Carabillo M, Vento R, Tesoriere G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci 1998; 39:1300-11.
21. Vento R, D'Alessandro N, Giuliano M, Lauricella M, Carabillo M, Tesoriere G. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress. Exp Eye Res 2000; 70:503-17.
22. Li A, Zhu X, Brown B, Craft CM. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2003; 44:996-1007.
23. Fassina G, Aluigi MG, Gentleman S, Wong P, Cai T, Albini A, Noonan DM. The cAMP analog 8-Cl-cAMP inhibits growth and induces differentiation and apoptosis in retinoblastoma cells. Int J Cancer 1997; 72:1088-94.
24. Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumour Biol 1998; 19:356-63.
25. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998; 10:573-80.
26. Pawelec G, Rees RC, Kiessling R, Madrigal A, Dodi A, Baxevanis C, Gambacorti-Passerini C, Masucci G, Zeuthen J. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncog 1999; 10:83-127.
27. Ben-Efraim S. One hundred years of cancer immunotherapy: a critical appraisal. Tumour Biol 1999; 20:1-24.
28. Younes HM, Amsden BG. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J Pharm Sci 2002; 91:2-17.
29. Valente G, Ozmen L, Novelli F, Geuna M, Palestro G, Forni G, Garotta G. Distribution of interferon-gamma receptor in human tissues. Eur J Immunol 1992; 22:2403-12.
30. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749-95.
31. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666-70.
32. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230:630-2.
33. Ryffel B, Brockhaus M, Greiner B, Mihatsch MJ, Gudat F. Tumour necrosis factor receptor distribution in human lymphoid tissue. Immunology 1991; 74:446-52.
34. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11:255-60.
35. Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ. Cell cycle-specific effects of tumor necrosis factor. Cancer Res 1984; 44:83-90.
36. Warren DJ, Slordal L, Moore MA. Tumor-necrosis factor induces cell cycle arrest in multipotential hematopoietic stem cells: a possible radioprotective mechanism. Eur J Haematol 1990; 45:158-63.
37. Pusztai L, Lewis CE, McGee JO. Growth arrest of the breast cancer cell line, T47D, by TNF alpha; cell cycle specificity and signal transduction. Br J Cancer 1993; 67:290-6.
38. Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, Zuckerman KS. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 2002; 277:16528-37.
39. Jeoung DI, Tang B, Sonenberg M. Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem 1995; 270:18367-73.
40. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48:2179-83.
41. van der Poll T, Levi M, Buller HR, van Deventer SJ, de Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174:729-32.
42. Naredi PL, Lindner PG, Holmberg SB, Stenram U, Peterson A, Hafstrom LR. The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma. Int J Cancer 1993; 54:645-9.
43. Syljuasen RG, Hong JH, McBride WH. Apoptosis and delayed expression of c-jun and c-fos after gamma irradiation of Jurkat T cells. Radiat Res 1996; 146:276-82.
44. Di Polo A, Farber DB. Rod photoreceptor-specific gene expression in human retinoblastoma cells. Proc Natl Acad Sci U S A 1995; 92:4016-20.
45. Shaaban SA, Deeb SS. Functional analysis of the promoters of the human red and green visual pigment genes. Invest Ophthalmol Vis Sci 1998; 39:885-96